Association of lymphocyte-mediated cytotoxicity (LMC) and antibody-dependent cell-mediated cytotoxicity (ADCC) with bone-marrow graft rejection in HLA-identical siblings.
D000920:Antibody-Dependent Cell Cytotoxicity; D000961:Antilymphocyte Serum / Q000627:therapeutic use; D016026:Bone Marrow Transplantation; D003520:Cyclophosphamide / Q000627:therapeutic use; D003602:Cytotoxicity, Immunologic; D004359:Drug Therapy, Combination; D006084:Graft Rejection; D006680:HLA Antigens; D006801:Humans; D011344:Procarbazine / Q000627:therapeutic use; D013601:T-Lymphocytes / Q000276:immunology; D014184:Transplantation, Homologous
D000961:Antilymphocyte Serum; D006680:HLA Antigens; D011344:Procarbazine; D003520:Cyclophosphamide